Analyst Price Target is C$0.00
This price target is based on 0 analysts offering 12 month price targets for CRH Medical in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a NaN upside from the last price of C$0.00.
Current Consensus is
The current consensus among 0 contributing investment analysts is to n/a stock in CRH Medical. This N/A consensus rating has held steady for over two years.
CRH Medical Corporation provides anesthesia services for patients undergoing endoscopic procedures in ambulatory surgical centers in the United States and Canada. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology to treat various grades of hemorrhoid. The company distributes CRH O'Regan system, treatment protocols, and operational and marketing expertise as a turnkey package directly to gastroenterology practices. It also offers a hemorrhoid banding ancillary program, cybersecurity, and a consumer-centric digital application. The company was formerly known as Medsurge Medical Products Corp. and changed its name to CRH Medical Corporation in April 2006. CRH Medical Corporation was founded in 2000 and is headquartered in Vancouver, Canada. As of April 22, 2021, CRH Medical Corporation operates as a subsidiary of WELL Health Technologies Corp.